Fondation Genevoise pour l'Innovation Technologique is a venture capital firm specializing in seed, start-up, and early-stage investments. It also provides incubatory services. It typically invests in pharmaceutical, healthcare, cleantech, telecommunication services, ICT, information technology, life sciences, nanotechnology, high tech, med tech, and tech innovative companies. The firm seeks to invest in companies based in Switzerland. It typically invests between CHF0.1 million ($.11 million) and CHF0.5 million ($.54 million) per equity transaction and structures its investments in the form of equity and convertible loans. It assumes upto three percent equity in every new company. The firm may also become a member of the board of directors of the portfolio companies. The firm makes balance sheet investments. Fondation Genevoise pour l'Innovation Technologique was founded in 1991 and is based at Plan-les-Ouates, Switzerland.

Swisscom is Switzerland's leading telecommunications and IT company, headquartered in Ittigen, near Bern. It holds a significant market share in both mobile and fixed-line services, operating under a regulatory environment that allows it to maintain higher pricing compared to competitors. The company also has substantial international activities, particularly in Italy through its subsidiary Fastweb, which provides broadband services. Swisscom Ventures, established in 2007 and based in Zurich, acts as the corporate venture capital arm of Swisscom, focusing on early-stage investments in technology companies within the telecommunications, IT infrastructure, artificial intelligence, and cybersecurity sectors. Additionally, Swisscom engages in sustainability initiatives through its StartUp Challenge, promoting innovations that contribute to climate protection. With around 21,500 employees, Swisscom is recognized as one of the most sustainable companies in Switzerland and Europe.

Redalpine is a prominent European venture capital firm based in Zurich, Switzerland, specializing in early-stage investments in highly scalable start-ups. Founded in 2007, Redalpine has launched multiple funds, including Redalpine Capital IV, V, VI, and VII, focusing on sectors such as information technology, healthcare, biotechnology, fintech, and energy. The firm typically invests between CHF 0.3 million and CHF 10 million per company, aiming to support 15 to 20 companies per fund. Redalpine's mission is to assist talented entrepreneurs in transforming ambitious visions into reality by providing financial resources, operational expertise, coaching, and access to a robust network. With approximately USD 1 billion in assets under management, Redalpine's interdisciplinary team actively engages with over 70 portfolio companies, offering sector-specific knowledge and international connections to enhance their growth potential.

VI Partners is a Swiss venture capital firm established in 2001, based in Altendorf. The firm specializes in investing in healthcare and technology sectors, particularly targeting university spin-offs and promising startups. VI Partners provides these companies with essential capital, coaching, and access to professional networks to help them grow and succeed. The firm serves as an advisor to multiple funds, with its first fund launched in collaboration with McKinsey & Company and the Swiss Federal Institute of Technology in Zürich (ETHZ). By bridging the gap between innovative entrepreneurs and savvy investors, VI Partners plays a crucial role in fostering the development of successful companies in Switzerland.

High-Tech Gründerfonds Management GmbH, established in 2005 and based in Bonn, Germany, is a venture capital firm that specializes in early-stage investments in high-tech startups across various sectors, including information and communication technology, software, healthcare, and life sciences. The firm focuses on companies that are less than one year old and have a turnover of less than €10 million. High-Tech Gründerfonds typically invests between €0.5 million and €3 million, acquiring a minority stake of up to 25% in its portfolio companies. The firm often acts as the lead investor and provides follow-on financing, having facilitated over €2 billion in additional funding from external investors. With a commitment to nurturing innovation, it has supported the development of more than 500 startups and has successfully exited over 100 investments. The firm’s backing includes participation from various public and private entities, reflecting its role as a key player in the German startup ecosystem.

Alpana Ventures is a venture capital firm headquartered in Geneva, Switzerland, with additional offices in Paris, France, and Saratoga, California. The firm specializes in seed and early-stage investments, focusing primarily on MedTech, fintech, mobility, marketplaces, and SaaS sectors. Alpana Ventures aims to leverage the technological expertise found in Switzerland and Europe, particularly in the context of digital transformation. By bridging European startups with opportunities in Silicon Valley, the firm provides its portfolio companies with access to resources such as experienced talent, venture growth capital, and potential M&A prospects. The firm typically invests in companies based in the Asia-Pacific region, Switzerland, and the United States, looking for innovative solutions in areas such as healthcare, information technology, finance, enterprise solutions, social media, gaming, and cybersecurity.

ACE & Company SA is a private equity and venture capital firm founded in 2005 and headquartered in Geneva, Switzerland, with additional offices in London, New York, Hong Kong, and Cairo. The firm specializes in direct investments across various stages, including angel, growth, buyout, special situations, and secondary investments, without being limited to specific sectors or regions. It offers early-stage investments between $0.05 million and $2 million to technology-based incubators in the consumer goods, services, and technology sectors, while growth-stage investments range from $5 million to $15 million. The firm also engages in late-stage buyouts and secondary market acquisitions, investing between $0.05 million and $5 million in private equity funds. ACE & Company emphasizes long-term relationships and a collaborative investment approach, aiming to provide unique access to value-adding and risk-managed opportunities. With a focus on developing a strong network and a reputation for trust and transparency, the firm has significantly expanded its assets over the years, establishing a respected presence in the global investment landscape.

CV VC is a next generation investment company where cutting-edge blockchain and crypto technology meet traditional venture capital. Based in the heart of Switzerland’s Crypto Valley, the company invests in all stages of crypto and blockchain development, from incubation to growth capital and has its own thriving ecosystem. CV VC is the leading blockchain advisory team in Crypto Valley. It covers critical stages of start-up life, including business model development, technology assessment & token model, communication strategy, and attracting capital and strategic partnerships.

btov Partners is a Berlin-based venture capital firm established in 2000, formerly known as BrainsToVentures. The firm specializes in early-stage investments, focusing on seed and series A rounds across sectors including life sciences, healthcare, industrial, and technology. btov manages a diverse portfolio, with institutional and partner funds that collectively oversee over EUR 420 million in assets. The firm invests approximately EUR 50 million annually, with individual investment amounts ranging from EUR 0.25 million to EUR 3.5 million, and can increase total commitments to as much as EUR 10 million across multiple financing rounds. btov has offices in Berlin, Munich, and St. Gallen, and has made notable investments in companies such as DataArtisans, DeepL, and Volocopter, among others.

UBS AG is a prominent global financial services firm that operates in wealth management, investment banking, and asset management. With a strong presence in various markets, UBS provides a wide array of services to individuals, families, institutions, and corporations. Its Global Asset Management division offers traditional and alternative investment solutions, including hedge funds, private equity, real estate, and infrastructure investments, catering to private clients and institutional investors. UBS also provides advisory and financial solutions through its investment banking arm, which is one of the leading firms in capital markets. The firm's wealth management services are designed to meet the needs of high net worth individuals, leveraging its extensive network and expertise to deliver tailored investment strategies. UBS operates in multiple countries, ensuring a diversified approach to asset management while maintaining a commitment to client service and performance.

Swisscanto Invest is the largest asset manager operating exclusively in Switzerland

BackBone Ventures AG is a venture capital firm established in 2018 and based in Zürich, Switzerland. The firm specializes in seed, start-up, growth capital, and early-stage investments, primarily targeting the information and communication technology, food technology, and disruptive technology sectors. With a focus on the DACH region and Israel, BackBone Ventures aims to identify promising start-ups and provide them with capital, expertise, and a robust network to foster their growth. The firm is committed to supporting innovative businesses that have the potential for profitability and sustainability, thereby contributing to positive societal impact and empowering the next generation of entrepreneurs.

Versant Ventures is a prominent healthcare investment firm headquartered in California, specializing in medical devices, biotechnology, and pharmaceuticals. Established in 1999, the firm manages approximately $2.3 billion and invests across all stages of company development, with a strong focus on discovering and developing innovative therapeutics. Versant has a global presence with offices in Canada, the U.S., and Europe, and its team comprises professionals with extensive investment, operational, and scientific expertise, allowing for a proactive approach to building companies. Since its inception, Versant has successfully facilitated the growth of over 65 companies, leading to numerous acquisitions and public offerings.

EQT is a private equity firm headquartered in Stockholm, Sweden, with additional offices across Europe, North America, and the Asia Pacific region. Established in 1994, the firm specializes in buyouts, expansion capital, and infrastructure investments, focusing on mid-market companies in sectors such as healthcare, technology, industrials, and services. EQT employs a responsible ownership approach and an industrial growth strategy, seeking opportunities in regions with significant growth potential, including Northern and Eastern Europe, Asia, and the United States. The firm invests through various strategies, including private capital, real assets, credit, and public value, and aims to acquire controlling or co-controlling stakes in its portfolio companies, often holding investments for four to eight years. EQT Life Sciences, a notable segment of the firm, targets innovative healthcare and life sciences companies.

Fortyone AG is a private equity investment firm based in St. Gallen, Switzerland, specializing in participations in non-listed companies. The firm takes an active investment approach, focusing on opportunities where they can contribute not only financial resources but also their knowledge, experience, and networks. To implement this "smart money" strategy effectively, Fortyone AG typically seeks involvement with the Board of Directors of its portfolio companies, allowing them to have a meaningful influence on corporate governance and development. The extent of their participation is determined by the specific needs of each investment, aligning their support with the goals of the companies they invest in.

M Ventures is an early-stage venture capital firm based in Los Angeles, California, established in 2017. The firm focuses on direct investments in technology companies, particularly those aligned with emerging cultural trends and behaviors in a diverse global marketplace. M Ventures aims to identify innovative ideas, technologies, and products that have the potential to become widely influential. Its investment strategy emphasizes early venture opportunities, seeking to support companies that can leverage shifts in consumer dynamics and technological advancements. Through its strategic approach, M Ventures actively contributes to the growth and success of its portfolio companies.

BioMedPartners is a prominent European venture capital firm based in Switzerland, with additional offices in Germany and Guernsey. Founded in 2003, the firm specializes in providing private equity and mezzanine financing to early- and mid-stage companies in the healthcare and life sciences sectors. BioMedPartners focuses on a wide range of areas within the industry, including pharmaceuticals, biotechnology, diagnostics, and medical technology. The firm's investment strategy emphasizes supporting innovative companies that are poised to make significant contributions to healthcare advancements.

Credit Suisse Group is a financial services company that advises clients in all aspects of finance. Credit Suisse First Boston (CSFB) is an arm of the Credit Suisse Group. Credit Suisse pursue a client-focused integrated bank strategy, focusing on complex client needs and value-adding businesses, leveraging the global expertise of our three divisions and reporting segments, Private Banking, Investment Banking, and Asset Management. It is their vision to become the world's premier and most admired bank, renowned for their expertise in private banking, investment banking, and asset management, and value for their advice, innovation, and execution. Their mission is to set new standards in partnering with their clients and providing them with innovative, integrated financial solutions. As a global bank serving clients in every region of the world, cultural diversity is essential to their success. They strive to create an open, respectful workplace that encourages people to work together and with their clients to deliver superior products, services, and results and support the success and prosperity of all their stakeholders.

Adveq, founded in 1997 and based in Zurich, Switzerland, is a prominent asset manager specializing in private equity and real asset funds on a global scale. The firm provides tailored investment solutions that enable clients to access select private market segments. With a strong track record, Adveq has invested in over 400 funds, consistently delivering returns across various economic cycles. Its clientele includes institutional investors such as pension funds, insurance companies, family offices, and other financial institutions from Europe, North America, and the Asia-Pacific region. Many investors have established long-term relationships with Adveq, valuing its role as a trusted partner in private market investing. Following its acquisition by Schroders in 2017, the firm rebranded to Schroder Adveq and maintains offices in key global financial centers including Frankfurt, London, New York, Beijing, Shanghai, and Hong Kong, along with an agent relationship in Sydney.

Polytech Ventures SA is a venture capital firm based in Ecublens, Switzerland, with an additional office in San Mateo, California. Established in 2008, the firm specializes in seed, early-stage, and Series A investments, primarily targeting high-tech startups in sectors such as fintech, digital health, cleantech, proptech, and life science tools and services. Polytech Ventures focuses on companies located in Switzerland but is also open to opportunities in Europe and the United States. The firm's initial investments typically range from CHF 0.1 million to CHF 0.5 million, with the potential to increase funding up to CHF 2.5 million as the companies grow. Its strategic presence at EPFL in Lausanne allows access to a vibrant innovation ecosystem, enhancing its ability to identify and support promising ventures.

Index Ventures is a venture capital firm established in 1996, with offices in London, San Francisco, and Geneva. The firm specializes in investing in high technology and life sciences, focusing on early-stage companies across various sectors including artificial intelligence, machine learning, fintech, healthcare, and entertainment. Index Ventures partners with innovative entrepreneurs who aim to transform their industries and has supported the growth of notable companies such as Adyen, Deliveroo, Dropbox, Farfetch, King, Slack, and Supercell. The firm's investment strategy typically involves allocating between $2 million to $20 million to promising ventures, primarily in Europe and the United States.

Helvetica Capital AG is a private equity investment firm based in Zurich, Switzerland, founded in 2015. The firm specializes in company succession within the middle market and primarily focuses on minority transactions. Helvetica Capital targets medium-sized companies, particularly in the healthcare, digital, and engineering sectors, and is also open to investing in early-stage companies and startups. The firm typically seeks investments in companies with a minimum revenue of CHF 20 million. By concentrating on Swiss companies, Helvetica Capital aims to support growth and development in the local market.

Novartis Venture Fund, established in 1996 and based in Basel, Switzerland, specializes in venture capital investments within the healthcare sector, particularly focusing on biotechnology and biopharma. The fund targets the development of novel therapeutics, medical devices, diagnostics, and drug delivery systems, prioritizing investments that address unmet medical needs and demonstrate significant clinical impact. Initial investments typically range from USD 100,000, with total funding potentially reaching USD 30 to 50 million over the lifespan of a company. Novartis Venture Fund emphasizes early-stage investments to foster company growth and is open to leading or co-leading deals, as well as participating in larger syndicates. Its investment strategy encompasses regions including the USA, Canada, Europe, and Asia-Pacific, with a keen interest in innovative science and experienced management teams.

Privilège Ventures is a venture capital firm based in Zürich, Switzerland, with an additional office in Lugano. As the venture capital arm of Privilège Management, it specializes in investing in seed and early-stage companies, primarily focusing on opportunities in Switzerland and the broader European market. The firm targets various sectors, including industrial technology, medical technology, wearables, and information and communications technology. Privilège Ventures manages the Privilège Capital Fund IV, which is dedicated to investing in 15 to 20 startups, with a minimum investment of USD 0.25 million and a commitment to supporting women-led ventures.

Sofinnova Partners is an independent venture capital firm headquartered in Paris, France, with a focus on the life sciences sector, including biopharmaceuticals, biotechnology, medical devices, and industrial biotechnology. Over its 45-year history, the firm has financed nearly 500 companies, primarily targeting start-ups, early-stage ventures, corporate spin-offs, and occasional turnaround situations. Sofinnova Partners actively sources investment opportunities and often serves as the first institutional investor in Series A financings, taking a lead role in its portfolio companies. The firm engages closely with entrepreneurs from the formation phase, holding board positions and guiding companies through their development until exit. While primarily investing throughout Europe, Sofinnova Partners also allocates a portion of its investments globally.

Novo Holdings, established in 1999, is the holding company of the Novo Group, primarily managing the investment assets of the Novo Nordisk Foundation. Based in Copenhagen, with additional offices in San Francisco and Boston, Novo Holdings focuses on two main investment categories: Life Science Investments, which encompasses funding life science companies at various stages of development, and Financial Investments, which entails managing a diversified portfolio of equity and fixed income securities. As a prominent life science investor, Novo Holdings aims to create long-term value while ensuring that the Foundation can distribute returns for scientific, social, and humanitarian purposes to enhance public health and welfare. The company has also developed initiatives such as Novo Seeds, which supports early-stage applied research in life sciences, and invests in later-stage life science companies through growth equity. Novo Holdings maintains a strategic influence over affiliated companies, aligning their operations with the values and objectives of the Novo Group.

Lakestar Advisors GmbH is a venture capital firm founded in 2012, headquartered in Zurich, Switzerland, with additional offices in Berlin, Germany, and London, United Kingdom. The firm specializes in investing in technology-driven companies across various sectors, including media and entertainment, fintech, travel technology, mobility, digital healthcare, artificial intelligence, and blockchain. Lakestar targets series A, early, mid, late venture, and growth-stage investments, typically ranging from €500,000 to €45 million. Since launching its first fund in 2013, Lakestar has managed over €1 billion across multiple early-stage and growth funds. The firm's notable early investments include Skype, Spotify, Facebook, and Airbnb, while its current portfolio features companies such as Opendoor, Oscar, and Revolut. Lakestar focuses on helping its portfolio companies expand into new markets, particularly in Europe and the United States, providing support in business development, recruitment, technology, and marketing.

Helvetia Holding AG, founded in 1858 and headquartered in St. Gallen, Switzerland, operates as a prominent insurance group offering both life and non-life insurance products across Europe. The company provides a comprehensive range of services, including life insurance, pension plans, annuity products, and various non-life insurance options such as property, motor vehicle, liability, health, and accident insurance. With a workforce of approximately 5,200 employees, Helvetia serves over 2.7 million customers across Switzerland, Germany, Austria, Spain, Italy, and France, as well as selected regions worldwide. Helvetia has evolved from several Swiss and foreign insurance companies into a successful entity with a business volume of CHF 7.5 billion. The group's investment and financing activities are supplemented through subsidiaries and fund companies in Luxembourg and Jersey, reflecting its commitment to broadening its reach and operational effectiveness.

Ringier AG is the largest Swiss media company, active internationally in Europe, Asia, and Africa. Founded in 1833, it has a long-standing history of producing over 120 newspapers and magazines, as well as operating printing plants, radio and television stations, and numerous web and mobile platforms. With approximately 8,000 employees, Ringier emphasizes independence, freedom of expression, and diversity of information. The company has adapted to changing media landscapes, launching successful ventures in digital media and entertainment. Notably, it established a joint venture with Axel Springer to enhance its presence in Central Europe. Ringier also invests in innovative digital start-ups through Ringier Digital Ventures AG. Throughout its history, the company has maintained a commitment to journalistic quality and excellence in its products.

Zühlke is a Swiss company founded in 1968 that supports businesses in transforming their ideas into successful market offerings. Operating across various locations including Austria, Germany, Serbia, Switzerland, and the United Kingdom, Zühlke covers all phases of the business innovation process, assisting companies from concept development to implementation and operation. Its venture capital arm, Zühlke Ventures AG, focuses on financing early-stage startups and providing growth capital, primarily in healthtech and technology sectors. The firm targets investments in the range of CHF0.5 million to CHF1 million, primarily in Swiss and US markets, but also in other German-speaking countries and the UK. Zühlke Ventures aims to hold minority stakes and typically seeks to exit investments within 6 to 10 years through trade sales.

Global Founders Capital (GFC) is a venture capital firm established in 2013 and headquartered in Berlin, Germany. The firm is stage agnostic, meaning it invests in companies at various stages of development, from early-stage ventures to those preparing for an initial public offering. GFC focuses on empowering talented entrepreneurs and seeks investment opportunities in sectors such as internet, retail, financial software, media, communication, and information technology. With a global perspective, GFC aims to support innovative companies across all continents.

Swiss Founders Fund is a seed and early stage investment fund based in St.Gallen, Switzerland. SFF invests in and builds companies globally.

Vontobel Asset Management is a global multi-boutique asset manager based in Basel, Switzerland, with a history dating back to 1924. The firm specializes in various investment strategies, including Quality Growth Equities, Multi-Asset Class, Fixed Income, Global Thematic Equities, and Alternatives, operating through independent boutiques that focus on specific areas of expertise. As of mid-2018, its investment portfolio comprised 33% multi-asset, 39% equity, and 29% fixed income. Vontobel is dedicated to expanding its Fixed Income boutique globally and enhancing its presence in the UK market. Additionally, Vontobel European Ventures, a venture capital fund located in Zurich, focuses on investments in the semiconductor and technology, media, and telecommunications sectors across Europe. In 2015, Vontobel Asset Management integrated Harcourt, which specializes in alternative investments, into its broader operational framework.

Momenta is an investment firm based in Zurich, Switzerland, focused on early-stage companies within the digital industry. As the investment arm of Momenta Partners, which has been operating since 2012, it specializes in sectors such as energy, manufacturing, smart spaces, and supply chain/logistics. Momenta leverages its deep industry experience and a global network to identify and support innovative companies that are poised to disrupt traditional markets. The firm aims to accelerate growth and enhance value by investing at various levels of the solution stack, facilitating the development of digital technologies that drive industry transformation.

Speedinvest GmbH is a venture capital firm founded in 2011 and based in Vienna, Austria, specializing in early-stage investments in technology-related startups across Europe. The firm focuses on sectors such as deep tech, fintech, health, industrial tech, consumer marketplaces, software as a service, and climate tech. Speedinvest typically invests between €0.25 million and €3 million in pre-seed to Series A stages, aiming to take minority stakes of up to 20% in its portfolio companies. The firm emphasizes operational support, often taking on active roles within the companies it invests in for periods ranging from six months to a year. With additional offices in cities including San Francisco, Berlin, Paris, London, and Munich, Speedinvest seeks to leverage a global network to enhance its contributions to Europe’s startup ecosystem.

TiVenture is a seed investment fund owned by the Fondazione Centenario Banca Stato that invests in early stage companies with innovative technologies and high growth potential, principally in southern Switzerland. TiVenture is actively looking and ready to support exceptional founders and entrepreneurs developing scalable products for the global market. TiVenture has a diversified portfolio of companies and is mainly active in the life science, medical, high-tech and IT sectors.

Fyrfly Venture Partners is a venture capital firm based in Menlo Park, California, that specializes in seed and early-stage investments in technology companies across the United States. Established in 2011, the firm emphasizes opportunities within the data and intelligence sectors. Its mission is to support innovative startups that leverage technology to drive growth and value.

Constantia New Business GmbH is a venture capital firm based in Vienna, Austria, founded in 2012. The firm specializes in early-stage investments, focusing on seed to Series A funding for innovative B2B technology companies. CNB targets businesses that demonstrate initial customer traction in sectors such as information technology, advanced manufacturing, measurement and inspection, material sciences, and robotics. With a strong emphasis on supporting passionate founding teams, the firm provides guidance particularly in sales and marketing to help scale their ventures. CNB maintains a long-term investment outlook and exclusively invests in companies located in Europe, seeking to partner with entrepreneurs who are developing transformative products that can impact their respective industries.

Outlier Ventures is a London-based venture platform founded in 2013 that focuses on investing in early-stage startups developing transformative technologies, particularly in the blockchain, AI, and IoT sectors. As a pioneer in blockchain investment in Europe, the firm has cultivated a robust investment thesis centered on the convergence of decentralized technologies with advancements in various fields, aiming to establish a new decentralized data infrastructure that supports the evolution of Web 3.0. Outlier Ventures not only provides financial backing but also offers extensive support through its Base Camp program, which serves as an incubation and acceleration platform for pre-seed projects, providing resources such as office space, legal assistance, and operational support. The firm has a dedicated team of specialists and operates globally, investing in a diverse range of sectors including gaming, NFTs, decentralized finance, and middleware.

Earlybird Venture Capital GmbH & Co. KG is a Berlin-based venture capital firm established in 1997, focusing on early-stage and growth investments in technology and healthcare sectors. The firm typically invests in disruptive consumer and enterprise internet businesses, mobility, logistics, and various technology-driven fields such as artificial intelligence, cloud computing, and fintech. Earlybird emphasizes companies located in Europe, particularly in German-speaking countries and Central Eastern Europe, while also considering opportunities in the United States and other regions. With over €1 billion under management, Earlybird aims to provide not only financial backing but also strategic support and access to a robust international network. The firm usually invests between €200,000 and €5 million in initial funding, with the potential for follow-on investments up to €15 million per portfolio company. Known for being one of the most experienced venture investors in Europe, Earlybird has a strong track record, including seven IPOs and 23 trade sales.

Forestay Capital is a venture capital firm focused on investing in the technology sector, particularly in Europe, Israel, and the East Coast of the United States. Established in 2017 and headquartered in Geneva, Switzerland, it aims to support innovative companies that leverage software and data to transform traditional business models. The firm seeks investment opportunities in revenue-generating technology companies, with a preference for sectors such as artificial intelligence, machine learning, data infrastructure, cybersecurity, productivity, and automation. Through its investments, Forestay Capital strives to help businesses achieve their growth ambitions by embracing forward-looking technologies.

Pureos Bioventures is a venture capital firm based in Zurich, Switzerland, focused on investing in private companies involved in innovative drug development. The firm emphasizes the next generation of biological drugs and novel drug formats, targeting advancements in the pharmaceutical sector. By concentrating on early-stage investments, Pureos Bioventures aims to support the growth of companies that are pioneering new therapeutic solutions.

Tiny VC is a venture capital firm based in London, United Kingdom, founded in 2017. The firm focuses on early-stage investments, particularly in pre-seed to seed-stage technology startups throughout Europe. By concentrating on this early investment phase, Tiny VC aims to support innovative entrepreneurs and help them grow their businesses in the competitive technology landscape.

Swiss Startup Group is a venture platform focused on scouting, building, accelerating, and investing in promising startups. Its investment arm, Swiss Startup Capital AG, provides exclusive access to early-stage venture capital investments, helping to unlock new opportunities in this asset class. Through its comprehensive approach, Swiss Startup Group supports entrepreneurs and fosters innovation within the startup ecosystem.

Sequoia Capital is a prominent venture capital firm founded in 1972 and based in Menlo Park, California. The firm specializes in investing across various stages of startups, including seed, early, and growth stages, and focuses on sectors such as technology, healthcare, financial services, internet, and mobile. Sequoia typically invests between $100,000 and $1 million in seed companies, $1 million to $10 million in early-stage ventures, and $10 million to $100 million in growth investments. The firm operates globally, with significant activities in regions like Israel, China, and India, where it partners with dynamic founders to build successful companies. Sequoia's extensive portfolio includes notable firms and offers valuable insights and resources, benefiting from decades of experience in the venture capital landscape.

HBM Healthcare Investments is a principal investment firm established in 2001 and based in Zug, Switzerland, with a focus on the biotechnology, human medicine, diagnostics, and medical technology sectors. The firm invests globally in approximately 40 mature emerging companies, primarily targeting private firms that demonstrate significant value creation potential. Approximately two-thirds of its portfolio consists of investments in unquoted companies, while the remainder includes public companies and funds. HBM Healthcare Investments has developed a distinctive market position through its strategic investments in firms whose products are either at advanced stages of development or already available in the market. This diversified approach allows the firm to leverage opportunities across Europe, Asia, and North America, contributing to its broad shareholder base and enhancing its investment capabilities.

Capital Transmission SA is a private equity firm based in Geneva and Zurich, Switzerland, founded in 2008 as a subsidiary of Banque Cantonale de Geneve. The firm specializes in providing growth capital and financial support to mature companies with strong profitability and capable management. It typically invests between CHF 0.5 million and CHF 15 million, focusing on companies generating sales between CHF 5 million and CHF 100 million. Capital Transmission primarily targets investments in various industries, excluding financial services, and is particularly known for its expertise in succession planning for family-owned businesses, management buyouts, and spin-offs. By taking minority stakes in its portfolio companies, the firm aims to build trusting relationships with management while allowing them to retain operational autonomy. Additionally, Capital Transmission is open to investments in France and potentially other neighboring countries, offering tailored financing solutions to facilitate growth initiatives.

Bpifrance Financement S.A. is a French financial institution that provides a range of financing solutions and support services aimed at fostering the growth of startups, small and medium-sized enterprises (SMEs), and mid-cap companies. It offers various financial products, including medium to long-term loans, export insurance, and leasing options for both tangible and intangible assets. Additionally, Bpifrance supports companies through consulting services, guarantees for bank financing, and training for executives. The organization also engages in direct investments and manages funds aimed at enhancing the financial landscape for businesses at different stages of their development. Established in 1980 and based in Maisons-Alfort, France, Bpifrance was formerly known as OSEO S.A. and rebranded in July 2013. It operates as a subsidiary of Bpifrance SA, reinforcing its commitment to bolstering the French economy through diversified financial solutions.

Debiopharm Group is a biopharmaceutical development specialist based in Lausanne, Switzerland, focusing on in-licensing promising biologics and small molecule drug candidates for global registration. The group aims to maximize the commercial potential of its products through out-licensing agreements with pharmaceutical partners for sales and marketing. It operates multiple investment arms, including the Debiopharm Innovation Fund, which invests in early-stage companies within the biotechnology, diagnostics, and digital health sectors, focusing on smart data and biomarker development. This fund typically invests between $1 million and $10 million, seeking minority stakes and board representation in its portfolio companies. Additionally, Debiopharm Investment engages in private equity and real estate investments, targeting mature companies in IT security and renewable sectors, as well as residential and commercial properties primarily in Western Europe. With a commitment to long-term investments and active involvement in corporate governance, Debiopharm Group drives its portfolio companies toward successful market exits.

Kurma Partners is a Paris-based venture capital firm established in 2009, focusing on early-stage investments in the healthcare and biotechnology sectors across Europe. The firm specializes in financing innovation from pre-creation to development capital, managing multiple funds, including the Kurma Biofund I, II, and the Kurma Diagnostics fund. Kurma Partners plays a significant role in supporting therapeutic and medical innovations, leveraging connections with leading research institutes and prestigious hospitals. The firm's investment interests encompass a wide range of areas, including oncology, life sciences, digital health, artificial intelligence, and big data, demonstrating a commitment to advancing healthcare technologies.